Kura Oncology Inc

KURA remains in a Stage 2 advancing regime with accelerating momentum under a Parabola pattern. However, price is currently extended well above the rising EMAs and into extreme overbought RSI and Options Score territory, making immediate entries unfavorable. We will wait for a pullback into the rising 9/20 EMA support zone for a selective speculative entry.

• ↑Q1 2026 ComSifty revenue $5.8M with 85 new patient starts.
• ↑2026 collaboration revenue guidance raised to $45–55M.
• ↓Q1 net loss $73.3M vs $57.4M prior year signals widening deficits.